Skip to content

Author

J. Codony-Servat

We have 2 of 82 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

MRAS, SHOC2, PP1C and YAP1 mRNA level variations at 72 hours of targeted therapy in KRAS G12C-mutant non-small cell lung cancer cell lines

Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...

A. Giménez-Capitán, D. Olmo-González, E. Martínez-Pérez et al. · 0 citations
Open access Aug 2026

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft

In the H2030 xenograft model, tumor growth was significantly inhibited by treatment with the three-drug combination of omeprazole, sotorasib, and selinexor, with no apparent toxic side-effects or weight loss observed.

Jessica González, Xue-Ting Cai, Wenjing Diao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.